PharmaCyte Biotech, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that PharmaCyte Biotech, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $0 | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | $0 | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | $0 | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | $0 | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | $0 | Jul 28, 2022 |
| FY2021 | Apr 30, 2020 | $0 | Aug 10, 2021 |
| FY2020 | Apr 30, 2019 | $0 | Aug 13, 2020 |
| FY2019 | Apr 30, 2018 | $0 | Aug 13, 2019 |
| FY2017 | Apr 30, 2017 | $0 | Jul 27, 2017 |
| FY2017 | Jan 31, 2017 | $0 | Jul 27, 2017 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Apr 30, 2015 | $0 | Jan 19, 2016 |
| FY2015 | Apr 30, 2014 | $0 | Jan 19, 2016 |
| FY2015 | Apr 30, 2013 | $12.2K | Jan 19, 2016 |
| FY2013 | Apr 30, 2012 | $66.6K | Jul 29, 2013 |
| FY2012 | Apr 30, 2011 | $76.0K | Aug 14, 2012 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Apr 30, 2017 | $0 | Jul 27, 2017 |
| FY2017 | Jan 31, 2017 | $0 | Jul 27, 2017 |
| FY2017 | Oct 31, 2016 | $0 | Jul 27, 2017 |
| FY2017 | Jul 31, 2016 | $0 | Jul 27, 2017 |
| FY2017 | Apr 30, 2016 | $0 | Jul 27, 2017 |
| FY2017 | Jan 31, 2016 | $0 | Jul 27, 2017 |
| FY2017 | Oct 31, 2015 | $0 | Jul 27, 2017 |
| FY2017 | Jul 31, 2015 | $0 | Jul 27, 2017 |
| FY2016 | Apr 30, 2015 | $0 | Jul 29, 2016 |
| FY2016 | Jan 31, 2015 | $0 | Jul 29, 2016 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $30.66M | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | $333.8K | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | ($4.32M) | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | ($4.24M) | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | ($3.55M) | Jul 28, 2022 |
| FY2021 | Apr 30, 2020 | ($3.83M) | Aug 10, 2021 |
| FY2020 | Apr 30, 2019 | ($4.07M) | Aug 13, 2020 |
| FY2019 | Apr 30, 2018 | ($6.83M) | Aug 13, 2019 |
| FY2017 | Apr 30, 2017 | ($1.16M) | Jul 27, 2017 |
| FY2017 | Jan 31, 2017 | ($1.28M) | Jul 27, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($4.38M) | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | ($8.52M) | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | ($6.46M) | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | ($4.39M) | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | ($3.62M) | Jul 28, 2022 |
| FY2021 | Apr 30, 2020 | ($3.83M) | Aug 10, 2021 |
| FY2020 | Apr 30, 2019 | ($4.10M) | Aug 13, 2020 |
| FY2019 | Apr 30, 2018 | ($6.98M) | Aug 13, 2019 |
| FY2018 | Apr 30, 2017 | ($4.44M) | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | ($6.07M) | Jul 27, 2017 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $438.4K | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | $407.4K | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | $468.5K | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | $690.9K | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | $916.2K | Jul 28, 2022 |
| FY2021 | Apr 30, 2020 | $301.2K | Aug 10, 2021 |
| FY2020 | Apr 30, 2019 | $460.1K | Aug 13, 2020 |
| FY2019 | Apr 30, 2018 | $2.00M | Aug 13, 2019 |
| FY2018 | Apr 30, 2017 | $1.18M | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | $1.41M | Jul 27, 2017 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($2.98M) | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | ($2.15M) | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | ($3.79M) | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | ($4.12M) | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | ($3.33M) | Jul 28, 2022 |
| FY2021 | Apr 30, 2020 | ($2.34M) | Aug 10, 2021 |
| FY2020 | Apr 30, 2019 | ($2.88M) | Aug 13, 2020 |
| FY2019 | Apr 30, 2018 | ($5.08M) | Aug 13, 2019 |
| FY2018 | Apr 30, 2017 | ($3.34M) | Jul 20, 2018 |
| FY2013 | Apr 30, 2013 | ($390.4K) | Jul 29, 2013 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $55.17M | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | $59.90M | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | $73.28M | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | $90.62M | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | $7.40M | Jul 28, 2022 |
| FY2021 | Apr 30, 2020 | $6.17M | Aug 10, 2021 |
| FY2020 | Apr 30, 2019 | $5.78M | Aug 13, 2020 |
| FY2019 | Apr 30, 2018 | $6.41M | Aug 13, 2019 |
| FY2018 | Apr 30, 2017 | $8.67M | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | $7.16M | Jul 27, 2017 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $3.28M | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | $20.39M | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | $586.6K | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | $704.4K | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | $724.8K | Jul 28, 2022 |
| FY2021 | Apr 30, 2020 | $1.08M | Aug 10, 2021 |
| FY2020 | Apr 30, 2019 | $742.9K | Aug 13, 2020 |
| FY2019 | Apr 30, 2018 | $644.2K | Aug 13, 2019 |
| FY2018 | Apr 30, 2017 | $580.2K | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | $637.6K | Jul 27, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $51.89M | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | $27.65M | Aug 11, 2025 |
| FY2025 | Apr 30, 2023 | $72.69M | Aug 11, 2025 |
| FY2024 | Apr 30, 2022 | $89.92M | Aug 13, 2024 |
| FY2023 | Apr 30, 2021 | $6.68M | Jul 31, 2023 |
| FY2022 | Apr 30, 2020 | $5.09M | Jul 28, 2022 |
| FY2021 | Apr 30, 2019 | $5.04M | Aug 10, 2021 |
| FY2020 | Apr 30, 2018 | $5.77M | Aug 13, 2020 |
| FY2019 | Apr 30, 2017 | $8.09M | Aug 13, 2019 |
| FY2018 | Apr 30, 2016 | $6.52M | Jul 20, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($84.97M) | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | ($115.63M) | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | ($115.96M) | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | ($111.65M) | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | ($107.41M) | Jul 28, 2022 |
| FY2021 | Apr 30, 2020 | ($103.86M) | Aug 10, 2021 |
| FY2020 | Apr 30, 2019 | ($100.03M) | Aug 13, 2020 |
| FY2019 | Apr 30, 2018 | ($95.96M) | Aug 13, 2019 |
| FY2018 | Apr 30, 2017 | ($89.14M) | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | ($84.69M) | Jul 27, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $15.17M | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | $50.18M | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | $68.04M | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | $85.40M | Jul 31, 2023 |
| FY2013 | Apr 30, 2013 | $199.3K | Jul 29, 2013 |
| FY2013 | Apr 30, 2012 | $15.7K | Jul 29, 2013 |
| FY2013 | Apr 30, 2011 | $57.2K | Jul 29, 2013 |
| FY2012 | Apr 30, 2010 | $716 | Aug 14, 2012 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 3 | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | (1) | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | 0 | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | 0 | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | (2) | Jul 28, 2022 |
| FY2014 | Apr 30, 2014 | 0 | Aug 4, 2014 |
| FY2014 | Apr 30, 2013 | 0 | Aug 4, 2014 |
| FY2013 | Apr 30, 2012 | 0 | Jul 29, 2013 |
| FY2012 | Apr 30, 2011 | 0 | Aug 14, 2012 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 3 | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | (1) | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | 0 | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | 0 | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | (2) | Jul 28, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 6.80M | Aug 11, 2025 |
| FY2025 | Apr 30, 2024 | 8.04M | Aug 11, 2025 |
| FY2024 | Apr 30, 2023 | 16.79M | Aug 13, 2024 |
| FY2023 | Apr 30, 2022 | 20.72M | Jul 31, 2023 |
| FY2022 | Apr 30, 2021 | 1.59M | Jul 28, 2022 |
| FY2021 | Apr 30, 2020 | 1.09M | Aug 10, 2021 |
| FY2020 | Apr 30, 2019 | 1.19B | Aug 13, 2020 |
| FY2019 | Apr 30, 2018 | 1.01B | Aug 13, 2019 |
| FY2018 | Apr 30, 2017 | 905.35M | Jul 20, 2018 |
| FY2017 | Apr 30, 2016 | 781.23M | Jul 27, 2017 |